Beam Therapeutics (BEAM) News Today $23.22 -0.79 (-3.29%) Closing price 04:00 PM EasternExtended Trading$23.48 +0.26 (+1.12%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Cathie Wood’s ARK focuses on Beam Therapeutics, Intuitive Machines stockMarch 25 at 8:48 PM | investing.comProficio Capital Partners LLC Buys Shares of 16,368 Beam Therapeutics Inc. (NASDAQ:BEAM)Proficio Capital Partners LLC purchased a new position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 16,368 shares of the company's stock, valued at approximately $4March 25 at 3:19 AM | marketbeat.comYiheng Capital Management L.P. Sells 337,658 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Yiheng Capital Management L.P. decreased its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 44.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 426,102 shares of theMarch 22 at 6:14 AM | marketbeat.comUpgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene TherapyMarch 22 at 12:10 AM | seekingalpha.comQ1 EPS Estimate for Beam Therapeutics Increased by AnalystBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Investment analysts at Leerink Partnrs upped their Q1 2025 EPS estimates for Beam Therapeutics in a research report issued to clients and investors on Tuesday, March 18th. Leerink Partnrs analyst M. Foroohar now forecasts that the company willMarch 21, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $16.09 Million Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Charles Schwab Investment Management Inc. lifted its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 3.1% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 648,945 shares of the company's stock after buying anMarch 21, 2025 | marketbeat.comQ1 EPS Forecast for Beam Therapeutics Boosted by AnalystMarch 21, 2025 | americanbankingnews.comAlphaQuest LLC Reduces Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)AlphaQuest LLC trimmed its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 92.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,610 shares of the company's stock after selling 33,583 shares duringMarch 20, 2025 | marketbeat.comNikko Asset Management Americas Inc. Purchases 404,782 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Nikko Asset Management Americas Inc. increased its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 11.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,957,611 shares of the company's stock aMarch 18, 2025 | marketbeat.comIs Beam Therapeutics Inc. (BEAM) the Best Growth Stock to Invest in for the Next 10 Years?March 16, 2025 | insidermonkey.comBank of New York Mellon Corp Increases Stake in Beam Therapeutics Inc. (NASDAQ:BEAM)Bank of New York Mellon Corp lifted its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 21.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 276,917 shares of the company's stock after purchasing an additional 49,March 16, 2025 | marketbeat.comFinancial Contrast: Beam Therapeutics (NASDAQ:BEAM) and Adaptive Biotechnologies (NASDAQ:ADPT)March 16, 2025 | americanbankingnews.comFY2025 EPS Estimate for Beam Therapeutics Lifted by AnalystMarch 16, 2025 | americanbankingnews.comCantor Fitzgerald Issues Positive Estimate for BEAM EarningsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Cantor Fitzgerald increased their FY2025 earnings estimates for shares of Beam Therapeutics in a research report issued on Wednesday, March 12th. Cantor Fitzgerald analyst R. Bienkowski now expects that the company will earn ($3.27) per share fMarch 15, 2025 | marketbeat.comBeam Therapeutics' (BEAM) "Overweight" Rating Reiterated at Cantor FitzgeraldMarch 15, 2025 | americanbankingnews.comBeam Therapeutics (NASDAQ:BEAM) Stock Price Down 7.2% - Here's What HappenedBeam Therapeutics (NASDAQ:BEAM) Stock Price Down 7.2% - Here's WhyMarch 14, 2025 | marketbeat.comQ1 EPS Estimates for Beam Therapeutics Lifted by WedbushBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities researchers at Wedbush boosted their Q1 2025 EPS estimates for shares of Beam Therapeutics in a research note issued to investors on Monday, March 10th. Wedbush analyst D. Nierengarten now forecasts that the company will post earningsMarch 14, 2025 | marketbeat.comBeam Therapeutics' (BEAM) "Overweight" Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating on shares of Beam Therapeutics in a research note on Wednesday.March 13, 2025 | marketbeat.comBeam Therapeutics price target raised to $64 from $56 at CitiMarch 13, 2025 | markets.businessinsider.comBeam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough MarketMarch 12, 2025 | msn.comBeam Therapeutics (NASDAQ:BEAM) Stock Rating Upgraded by Jones TradingJones Trading raised Beam Therapeutics from a "hold" rating to a "buy" rating and set a $34.00 target price for the company in a report on Monday.March 11, 2025 | marketbeat.comScotiabank Upgrades Beam Therapeutics (BEAM)March 11, 2025 | msn.comBeam Therapeutics upgraded yesterday at Scotiabank after positive AATD dataMarch 11, 2025 | markets.businessinsider.comBeam Therapeutics (NASDAQ:BEAM) Sees Unusually-High Trading Volume - Still a Buy?Beam Therapeutics (NASDAQ:BEAM) Sees Strong Trading Volume - What's Next?March 11, 2025 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Beam Therapeutics in a research report on Monday.March 11, 2025 | marketbeat.comWedbush Reaffirms Outperform Rating for Beam Therapeutics (NASDAQ:BEAM)Wedbush reiterated an "outperform" rating and issued a $57.00 target price on shares of Beam Therapeutics in a research note on Monday.March 11, 2025 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Rating Increased to Sector Outperform at ScotiabankScotiabank raised Beam Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $40.00 price target on the stock in a research report on Monday.March 11, 2025 | marketbeat.comProficio Capital Partners LLC Makes New $406,000 Investment in Beam Therapeutics Inc. (NASDAQ:BEAM)Proficio Capital Partners LLC bought a new position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 16,368 shares of the company's stock,March 11, 2025 | marketbeat.comJones Trading Upgrades Beam Therapeutics (BEAM)March 11, 2025 | msn.comBeam Therapeutics Shares Drop After $500M Offering PricesMarch 10, 2025 | marketwatch.comBeam Therapeutics: Single-Base Editing Seems To WorkMarch 10, 2025 | seekingalpha.comIs Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now?March 10, 2025 | msn.comBeam Therapeutics upgraded to Outperform from Sector Perform at ScotiabankMarch 10, 2025 | markets.businessinsider.comBeam Therapeutics announces ‘positive’ data from study of BEAM-302March 10, 2025 | markets.businessinsider.comBeam Therapeutics Announces Pricing of Underwritten OfferingMarch 10, 2025 | globenewswire.comBeam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing MutationMarch 10, 2025 | globenewswire.comBeam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Rating of "Moderate Buy" from AnalystsBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the thirteen brokerages that are currently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, eight have assigned aMarch 10, 2025 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Stock Holdings Boosted by Vestmark Advisory Solutions Inc.Vestmark Advisory Solutions Inc. lifted its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 29.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 173,152 shares of the company's stock after acquiring an additional 39,250 shares duMarch 7, 2025 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Trading 7.9% Higher on Analyst UpgradeBeam Therapeutics (NASDAQ:BEAM) Stock Price Up 7.9% on Analyst UpgradeMarch 5, 2025 | marketbeat.comBeam Therapeutics price target raised to $25 from $24 at ScotiabankMarch 3, 2025 | markets.businessinsider.comBeam Therapeutics (NASDAQ:BEAM) Price Target Raised to $25.00 at ScotiabankScotiabank lifted their target price on Beam Therapeutics from $24.00 to $25.00 and gave the stock a "sector perform" rating in a report on Monday.March 3, 2025 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $80.00 target price on shares of Beam Therapeutics in a research note on Friday.March 1, 2025 | marketbeat.comResearch Analysts Offer Predictions for BEAM FY2025 EarningsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities researchers at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for shares of Beam Therapeutics in a research report issued on Wednesday, February 26th. Cantor Fitzgerald analyst R. Bienkowski now expects that the coMarch 1, 2025 | marketbeat.comQ2 Earnings Estimate for BEAM Issued By Leerink PartnrsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities research analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for shares of Beam Therapeutics in a report issued on Tuesday, February 25th. Leerink Partnrs analyst M. Foroohar forecasts that the company will poMarch 1, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Beam Therapeutics (BEAM)March 1, 2025 | markets.businessinsider.comGuggenheim Reiterates "Buy" Rating for Beam Therapeutics (NASDAQ:BEAM)Guggenheim restated a "buy" rating and set a $78.00 price objective on shares of Beam Therapeutics in a report on Thursday.February 28, 2025 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Stock Price Down 5.9% - Here's WhyBeam Therapeutics (NASDAQ:BEAM) Stock Price Down 5.9% - Here's What HappenedFebruary 27, 2025 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Price Target Raised to $26.00Royal Bank of Canada raised their price target on shares of Beam Therapeutics from $24.00 to $26.00 and gave the stock a "sector perform" rating in a report on Wednesday.February 27, 2025 | marketbeat.comQ1 Earnings Forecast for BEAM Issued By Leerink PartnrsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Beam Therapeutics in a note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn ($1.26) per shFebruary 27, 2025 | marketbeat.comQ1 EPS Estimate for Beam Therapeutics Reduced by AnalystBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities research analysts at Wedbush decreased their Q1 2025 earnings estimates for Beam Therapeutics in a research note issued on Tuesday, February 25th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($1.21) per shaFebruary 27, 2025 | marketbeat.com Remove Ads Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address BEAM Media Mentions By Week BEAM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BEAM News Sentiment▼1.060.68▲Average Medical News Sentiment BEAM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BEAM Articles This Week▼117▲BEAM Articles Average Week Remove Ads Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PCVX News QGEN News ROIV News SRPT News RVMD News BBIO News LNTH News TGTX News LEGN News AXSM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BEAM) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
